Recurrences were most common in the first 2 years after surgery for upper tract urothelial carcinoma (UTUC), and warrant intensive surveillance.

Updated thresholds outperform those recommended by American Thyroid Association guidelines for patients with medullary thyroid cancer.

Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.